Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.
Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.
Here are the five articles published in the print publication of Managed Healthcare Executive that had the most pageviews when they were posted on the MHE website.
The approval of Mounjaro (tirzepatide) for weight loss could be a tipping point for weight-loss drugs. [The weight-loss version of tirzepatide is being sold under the brand-name Zepbound.]
As many as 10 Humira biosimilars [it wound up being just 8] may be on the U.S. market before 2023 is over. AbbVie has taken several steps to protect its revenues, including the launches of Skyrizi and Rinvoq.
Pharmacy benefit managers say they exclude high-cost drugs and have alternatives on their formularies. Critics say exclusions narrow patient options and may put effective medication financially out of reach.
Repositories of donated drugs in 13 states are redistributing oncology medications to those in need.
Three ADCs are in late-stage trials as treatments for patients with non-small cell lung cancer.
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More